Loading…
angioedema
disease characterized by the rapid swelling
Details
- Instance of
- rare disease, type of disease
- Subclass of
- vascular skin disease, urticaria
- drug or therapy used for treatment
- fluoxymesterone, epinephrine / lidocaine, Hydrochlorothiazide / Lisinopril, omalizumab, (R)-carbinoxamine, cyproheptadine, cyproheptadine hydrochloride
- health specialty
- emergency medicine
- ICD-9-CM
- 995.1
- risk factor
- Nucynta
Connected on Wikidata
Subject of
- Determination of Specific Biomarkers of Angioneurotic Crisis
- An Open-label Drug-Drug Interaction Study to Evaluate the Effect of BCX7353 on Cytochrome P450 Enzyme Activity Using Probe Substrates
- Long-term Safety and Efficacy Study of DX-2930 (SHP643) to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE
- Analysis of the Availability of the Treatments for ACE-I and ARB-induced Angioedema
- FIRAZYR General Drug Use-Results Survey (Japan)
- Hereditary AngioEdema, Neurobiology and Psychopathology
- 12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
- Study to Evaluate the Real-World Long-Term Effectiveness of Lanadelumab in Participants With Hereditary Angioedema (HAE)
- Mepolizumab in Episodic Angioedema With Eosinophilia
- Hereditary Angioedema Kininogen Assay
- A Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) Study of Lanadelumab to Prevent Hereditary Angioedema (HAE) Attacks in Pediatric Participants of 2 Years to Less Than (<) 12 Years of Age
Nothing in the MetaHistoryBook collection references this item yet.